Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2009

Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D

Abstract excerpt

BACKGROUND: Some patients with glioblastoma multiform do not respond to temozolomide even though they have aberrant promoter methylation of the DNA repair enzyme O(6)-methylguanine methyltransferase (MGMT). This suggests that additional factors hamper temozolomide cytotoxicity. We aimed to confirm first that temozolomide is a target for the multidrug resistance transporter MDR1/ABCB1 and second to investigate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Brain Neoplasms

Share to Dacarbazine

Share to Glioblastoma

Share to K562 Cells

Share to Temozolomide

Source

Identifiers

PMID: 18687982
DOI: 10.1093/annonc/mdn548

Genes

MGMT
ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.PMID 18687982Read ↗

ABCB1 Polymorphisms Influence on Temozolomide Resistance and Overall Survival in Glioblastoma Patients: A Systematic Review of Clinical Evidence.Semantic proximity Read ↗

Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.Semantic proximity Read ↗

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.Semantic proximity Read ↗

Aldehyde dehydrogenase 1A1—a new mediator of resistance to temozolomide in glioblastomaSemantic proximity Read ↗

Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.Semantic proximity Read ↗

Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.Semantic proximity Read ↗

The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia.Semantic proximity Read ↗

Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.Semantic proximity Read ↗

Significance of MDR1 and multiple drug resistance in refractory human epileptic brainSemantic proximity Read ↗

The C3435T polymorphism of MDR1 and susceptibility to adult glioma.Semantic proximity Read ↗

Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.